(3) Aldo-keto reductase family 1 member C3 (AKR1C3) [27]: In AML and T-cell acute lymphoblastic leukemia (T-ALL), AKR1C3 expression in the tumor cell cytoplasm degrades doxorubicin hydrochloride, causing treatment resistance. The gene discussed is AKR1C3; the disease is neoplasm.